RATIONALE AND OBJECTIVES: In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS: We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS: Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS: Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.

Department of Organic Technology ICT Laboratory of Medicinal Diagnostics Technicka 5 Prague 6 166 28 Czech Republic

Department of Pharmacology 3rd Faculty of Medicine Charles University Ruska 87 Prague 10 100 34 Czech Republic

Zobrazit více v PubMed

J Physiol Pharmacol. 2004 Mar;55(1 Pt 2):137-54 PubMed

Physiol Rev. 2003 Jul;83(3):1017-66 PubMed

J Neurosci. 2001 Jul 15;21(14 ):5344-50 PubMed

Science. 1997 Jun 27;276(5321):2048-50 PubMed

Pharmacol Biochem Behav. 1996 Apr;53(4):809-16 PubMed

Psychopharmacology (Berl). 2014 Jul;231(14):2899-908 PubMed

Psychopharmacology (Berl). 2003 Jul;168(1-2):164-9 PubMed

Curr Opin Lipidol. 2007 Apr;18(2):129-40 PubMed

Nature. 1999 Dec 9;402(6762):656-60 PubMed

Eur J Neurosci. 2004 Oct;20(7):1849-57 PubMed

Addict Biol. 2012 May;17(3):613-22 PubMed

Psychopharmacology (Berl). 2010 Sep;211(4):415-22 PubMed

Psychopharmacology (Berl). 1998 Feb;135(4):324-32 PubMed

Br J Pharmacol. 2004 Nov;143(5):520-3 PubMed

J Lipid Res. 2005 Feb;46(2):342-9 PubMed

Annu Rev Psychol. 2003;54:25-53 PubMed

Curr Drug Targets CNS Neurol Disord. 2005 Dec;4(6):633-42 PubMed

FEBS Lett. 1996 Sep 16;393(2-3):231-5 PubMed

Psychopharmacology (Berl). 2001 Nov;158(3):259-66 PubMed

Br J Nutr. 2004 Nov;92 (5):757-61 PubMed

Alcohol. 2011 Jun;45(4):341-7 PubMed

Neurochem Int. 2009 Feb;54(2):89-94 PubMed

Pharmacol Rev. 2011 Jun;63(2):348-65 PubMed

J Neurosci. 2005 Jun 8;25(23 ):5645-50 PubMed

Addict Biol. 2012 Nov;17(6):956-63 PubMed

Eur J Neurosci. 2003 Dec;18(11):3145-9 PubMed

PLoS One. 2008 Mar 12;3(3):e1797 PubMed

Biochem Pharmacol. 1995 Jun 29;50(1):83-90 PubMed

Brain Res. 2001 Apr 13;898(1):178-80 PubMed

Neuropharmacology. 2005 Dec;49(8):1189-200 PubMed

Nat Rev Neurosci. 2003 Nov;4(11):873-84 PubMed

Front Neurosci. 2013 Sep 25;7:171 PubMed

Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97 PubMed

ACS Chem Neurosci. 2012 May 16;3(5):407-17 PubMed

Br J Pharmacol. 2008 May;154(2):369-83 PubMed

Eur J Neurosci. 1998 Nov;10(11):3565-71 PubMed

Psychopharmacology (Berl). 1999 Feb;142(1):85-94 PubMed

Nature. 1994 Dec 15;372(6507):686-91 PubMed

J Neurosci. 2007 Apr 4;27(14):3695-702 PubMed

J Pharmacol Exp Ther. 2003 Jul;306(1):93-102 PubMed

J Neurochem. 1992 May;58(5):1620-5 PubMed

Pharmacol Biochem Behav. 1985 Jan;22(1):101-5 PubMed

CNS Drug Rev. 2006 Spring;12(1):21-38 PubMed

Regul Pept. 2011 Dec 10;172(1-3):77-80 PubMed

J Neurosci. 1990 Jul;10(7):2308-17 PubMed

Science. 1992 Dec 18;258(5090):1946-9 PubMed

J Neurosci. 2006 Oct 25;26(43):11052-60 PubMed

Neuropsychopharmacology. 2006 Apr;31(4):804-13 PubMed

Psychopharmacology (Berl). 2013 Jan;225(1):241-50 PubMed

Life Sci. 1986 Jan 20;38(3):241-9 PubMed

Neuroscience. 2011 Sep 29;192:500-6 PubMed

Eur J Pharmacol. 2001 Jun 15;421(3):R1-3 PubMed

Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8 PubMed

Brain Res. 2004 Nov 12;1026(2):244-53 PubMed

Neuropsychopharmacology. 2005 Nov;30(11):2046-57 PubMed

Behav Brain Res. 2002 Dec 2;137(1-2):75-114 PubMed

Drug Alcohol Depend. 2011 Sep 1;117(2-3):126-31 PubMed

J Med Chem. 2007 Nov 15;50(23):5790-806 PubMed

The Role of Ghrelin/GHS-R1A Signaling in Nonalcohol Drug Addictions

Cannabinoid-Induced Conditioned Place Preference, Intravenous Self-Administration, and Behavioral Stimulation Influenced by Ghrelin Receptor Antagonism in Rats

Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin

Ghrelin Receptor Antagonism of Methamphetamine-Induced Conditioned Place Preference and Intravenous Self-Administration in Rats

Alterations in Rat Accumbens Endocannabinoid and GABA Content during Fentanyl Treatment: The Role of Ghrelin